Jazz Pharmaceuticals has a total of 3114 patents globally, out of which 1360 have been granted. Of these 3114 patents, more than 60% patents are active. The USA is where Jazz Pharmaceuticals has filed the maximum number of patents, followed by European Countries, it has generated an annual revenue of $3.7 billion in the year 2022. Parallelly, the UK seems to be the main focused R&D centre of Jazz Pharmaceuticals.
Jazz Pharmaceuticals was founded in the year 2005. Company is a biopharmaceutical company based in Ireland. As of March 2023, Jazz Pharmaceuticals has a market cap of $8.76 Billion.
Do read about some of the most popular patents of Jazz Pharmaceuticals which have been covered by us in this article and also you can find Jazz Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Jazz Pharmaceuticals patent portfolio.
How many patents does the CEO of Jazz Pharmaceuticals have?
The CEO, Bruce C Cozadd, has 0 patents.
How many patents does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has a total of 3114 patents globally. These patents belong to 545 unique patent families. Out of 3114 patents, 1879 patents are active.
How Many Patents did Jazz Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Jazz Pharmaceuticals Applications Filed | Jazz Pharmaceuticals Patents Granted |
| 2022 | 84 | 170 |
| 2021 | 200 | 134 |
| 2020 | 366 | 154 |
| 2019 | 188 | 83 |
| 2018 | 187 | 102 |
| 2017 | 133 | 82 |
| 2016 | 127 | 85 |
| 2015 | 156 | 68 |
| 2014 | 137 | 60 |
| 2013 | 80 | 45 |
| 2012 | 194 | 58 |
| 2011 | 98 | 37 |
Which Jazz Pharmaceuticals Drug Patents are Expiring in the Next 10 Years?
The patent no. US9050302B2 which is expiring in Mar, 2033, describing safely giving gamma hydroxybutyrate (GHB) along with monocarboxylate transporter (MCT) inhibitors for therapeutic reasons involves checking if the patient is using or will use valproate. If so, a lower dose of GHB or its salt is orally administered to reduce the combined effects of GHB and valproate.
Given below is the list of few drugs patented by Jazz Pharmaceuticals accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Xywav | US9050302B2 | Method of administration of gamma… | Mar, 2033 |
| Xyrem | US11253494B2 | Method of administration of gamma… | Mar, 2033 |
| Defitelio | US11746348B2 | Euglobulin-based method for deter… | Jun, 2032 |
| Zepzelca | US7763615B2 | Ecteinascidin analogs for use… | Dec, 2029 |
Interested in knowing about Jazz Pharmaceutical’s Drug Patents Expiring in the next 10 years?
How many Jazz Pharmaceuticals patents are Alive/Dead?
How Many Patents did Jazz Pharmaceuticals File in Different Countries?
Countries in which Jazz Pharmaceuticals Filed Patents
| Country | Patents |
| United States Of America | 441 |
| Europe | 247 |
| United Kingdom | 233 |
| Japan | 160 |
| Canada | 157 |
| Australia | 151 |
| Hong Kong (S.A.R.) | 110 |
| Mexico | 100 |
| China | 100 |
| Germany | 99 |
| Israel | 96 |
| Korea (South) | 96 |
| Spain | 91 |
| Brazil | 75 |
| India | 54 |
| Taiwan | 52 |
| New Zealand | 50 |
| Denmark | 49 |
| Singapore | 45 |
| Portugal | 41 |
| South Africa | 35 |
| Norway | 33 |
| Poland | 31 |
| Austria | 23 |
| Russia | 21 |
| Malaysia | 18 |
| Argentina | 18 |
| Hungary | 18 |
| Slovenia | 16 |
Where are Research Centres of Jazz Pharmaceuticals Patents Located?
10 Best Jazz Pharmaceuticals Patents
US20030235619A1 is the most popular patent in the Jazz Pharmaceuticals portfolio. It has received 143 citations so far from companies like Nanocarrier Co, Oshadi Drug Administration, and Bind Biosciences.
Below is the list of 10 most cited patents of Jazz Pharmaceuticals:
| Publication Number | Citation Count |
| US20030235619A1 | 143 |
| US7668730B2 | 110 |
| WO2004016246A1 | 109 |
| WO2009007697A1 | 103 |
| US8263650B2 | 100 |
| US7025992B2 | 100 |
| US6730330B2 | 98 |
| US6472431B2 | 96 |
| WO2015193668A1 | 94 |
| US6780889B2 | 90 |
Which Companies are using Jazz Pharmaceuticals Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Jazz Pharmaceuticals patent portfolio are GW Pharmaceuticals, US Govt, and Bank of America.
List of the top forward citing Companies –
| Company | Number of Patents |
| GW Pharmaceuticals | 28 |
| National Institutes Of Health (NIH) US Dept Of Health And Human Services (Dhhs) US Government | 9 |
| Bank Of America | 9 |
| Celator Pharmaceuticals | 6 |
| India Globalization Capital | 5 |
| Canntab Therapeutics | 4 |
| Zuli Holdings | 4 |
| Cerulean Pharma | 4 |
| Canopy Growth Corporation | 4 |
| Elwha | 4 |
Count of 102 and 103 Type Rejections based on Jazz Pharmaceuticals Patents
Top Jazz Pharmaceuticals Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US6730330B2 | 19 |
| US7088914B2 | 14 |
| US7700368B2 | 14 |
| US7344736B2 | 11 |
| US20080299205A1 | 11 |
| US20030147945A1 | 10 |
| US8673368B2 | 10 |
| US7025992B2 | 10 |
| US20050118249A1 | 9 |
| US7622140B2 | 9 |
| US6946150B2 | 9 |
| US7968594B2 | 7 |
| US10004684B2 | 7 |
| US9034395B2 | 6 |
| US20030235619A1 | 6 |